Hydrix Limited (HYD) AI Stock Analysis

• Market Cap: AU$4.36M
• Dividend Yield: N/A
• Average Volume (3M): 316.59K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.44
• Revenue Growth: -4.86%
• EPS Growth: 64.36%
• Country: AU
• Employees: 55
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): -0.01
• Shares Outstanding: 272,768,860
• 10 Day Avg. Volume: 341,547
• 30 Day Avg. Volume: 316,588
• PEG Ratio: 0.02
• Price to Book (P/B): -0.55
• Price to Sales (P/S): 0.33
• P/FCF Ratio: -6.17
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: AU$0.01 ▼(-40.00% Downside)

Hydrix Limited's overall stock score is primarily impacted by its financial instability, including declining revenue and negative equity. The technical analysis further indicates a bearish trend, while the valuation is unattractive due to negative earnings. The absence of earnings call data and corporate events leaves these areas unaddressed.

Positive Factors

High Gross Profit Margin

A high gross profit margin indicates efficient production and strong pricing power, which can support profitability if operational costs are managed.

Improvement in Free Cash Flow

Growth in free cash flow suggests better cash management and potential to fund operations or investments without relying on external financing.

Innovative Product Offerings

Hydrix's focus on innovation in medical devices positions it well in a growing healthcare market, potentially driving future revenue growth.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in maintaining market share or product demand, which could hinder long-term financial stability.

Negative Operating Cash Flow

Negative operating cash flow suggests the company struggles to cover its operational costs, which could lead to liquidity issues if not addressed.

Weak Balance Sheet

A weak balance sheet with negative equity raises concerns about solvency and limits financial flexibility to invest in growth opportunities.

Hydrix Limited Business Overview & Revenue Model

Company Description

Hydrix Limited provides product design, engineering, and regulatory services in Australia, Singapore, Europe, North America, and internationally. It operates through two segments: Hydrix Services and Hydrix Medical. It provides cardiovascular products, such as The GUARDIAN, a cardiac monitoring and alerting device that reduces the stresses of living; Phyzhon PHYRARI FFR-Wire enables cardiologists to combine diagnosis procedures with delivery of therapy including stents; and LUDO, a customizable plug-and-play platform that provides critical tools to start MCS pump development. The company also offers a range of services, including product development, regulatory and clinical consulting, and technology commercialization. It serves medical, consumer, industrial, utilities, defense, aerospace, and mining industries. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia

How the Company Makes Money

Hydrix Limited generates revenue through multiple streams, primarily by selling its medical devices and software solutions to hospitals, clinics, and healthcare providers. The company also earns income from engineering services, which include product development and consulting for third-party clients in the medical field. Additionally, Hydrix may establish partnerships with other healthcare technology firms to co-develop products or share expertise, further contributing to its revenue. The company's ability to secure contracts and maintain relationships with key stakeholders in the healthcare industry is crucial for its financial performance.

Hydrix Limited Financial Statement Overview

Summary

Hydrix Limited is facing significant financial challenges, including declining revenue, persistent losses, and a weak balance sheet with negative equity. Despite some improvement in free cash flow, the negative operating cash flow and profitability metrics indicate ongoing financial instability.

Income Statement

Hydrix Limited has experienced a decline in revenue over the past year, with a negative revenue growth rate of -2.24%. The company is also facing challenges in profitability, as indicated by a negative net profit margin and EBIT margin. Although the gross profit margin is relatively high at 94.44%, the overall profitability is hindered by significant net losses.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, resulting in an undefined debt-to-equity ratio. The company's return on equity is negative, indicating losses relative to shareholder investment. The equity ratio is also negative, highlighting potential solvency issues.

Cash Flow

Hydrix Limited shows some improvement in free cash flow growth at 45.46%, but operating cash flow remains negative, indicating ongoing cash flow challenges. The free cash flow to net income ratio is not meaningful due to negative net income, suggesting difficulties in generating cash relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.09M	10.09M	10.61M	13.16M	10.33M	7.45M
Gross Profit	9.53M	9.53M	9.79M	-638.73K	-3.31M	-6.46M
EBITDA	-1.40M	-1.40M	-7.92M	1.30M	-4.05M	-6.34M
Net Income	-2.92M	-2.92M	-9.56M	-396.93K	-5.55M	-9.78M
Balance Sheet
Total Assets	8.35M	8.35M	8.62M	14.58M	15.94M	19.38M
Cash, Cash Equivalents and Short-Term Investments	297.88K	297.88K	914.27K	1.15M	1.94M	6.65M
Total Debt	7.98M	7.98M	7.61M	4.73M	5.40M	5.97M
Total Liabilities	14.39M	14.39M	11.98M	8.22M	12.66M	13.67M
Stockholders Equity	-6.04M	-6.04M	-3.36M	6.35M	3.28M	5.71M
Cash Flow
Free Cash Flow	-535.13K	-535.13K	-1.91M	-3.32M	-6.75M	-3.35M
Operating Cash Flow	-527.01K	-527.01K	-1.89M	-3.12M	-6.58M	-2.86M
Investing Cash Flow	-54.20K	-54.20K	-53.43K	-209.71K	-306.65K	-641.56K
Financing Cash Flow	378.60K	-36.31K	1.71M	2.16M	1.72M	7.53M

Hydrix Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HYD, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.32 is Neutral, neither overbought nor oversold. The STOCH value of 183.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HYD.

Hydrix Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
KNO	42 Neutral	AU$6.92M	-4.44	-23.31%	―	2.15%	-900.00%
X2M	41 Neutral	AU$10.13M	―	―	―	-51.64%	-21.74%
HYD	40 Underperform	AU$4.36M	-1.19	―	―	-4.86%	64.36%
SIS	39 Underperform	AU$5.39M	―	―	―	-26.58%	―
DVL	39 Underperform	AU$59.65M	-26.50	-78.66%	―	-13.40%	4.76%
BCC	38 Underperform	AU$8.47M	-0.63	-135.89%	―	-21.60%	-657.00%

Hydrix Limited Corporate Events

Hydrix Limited Sees Continued Revenue Growth and Expands Internationally

Hydrix Limited reported a strong second consecutive quarter of revenue growth for its Hydrix Services segment, with sales reaching $3.35 million, 80% of which were international. The company added two new clients in the USA and Europe, and its ongoing projects with 15 clients suggest potential future revenue of over $35 million. Hydrix Medical is advancing sales of its cardiac monitoring software, while Gyder Surgical, a Hydrix Venture company, is preparing for its first-in-human surgical cases in the USA and raising capital for market expansion. Despite a $0.57 million operating loss, this marks a 25% improvement from the previous quarter, supported by a $2.5 million Letter of Comfort from major shareholders.

Hydrix Limited Announces 2025 Annual General Meeting Details

Hydrix Limited has announced the details for its upcoming Annual General Meeting, scheduled for November 27, 2025, in Melbourne. Shareholders are encouraged to submit written questions in advance regarding the company’s operations and audit reports. The meeting will provide an opportunity for shareholders to engage with the company’s board and discuss matters such as the Remuneration Report. Voting procedures have been outlined, allowing shareholders to appoint proxies if they cannot attend in person.

Hydrix Limited Releases 2025 Corporate Governance Statement

Hydrix Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, detailing the roles of the board and management, and the processes for appointing directors. This announcement reaffirms Hydrix’s commitment to transparency and accountability, potentially enhancing investor confidence and stakeholder trust.

Hydrix Limited Unveils Strategic Growth in Annual Report

Hydrix Limited’s annual report highlights its commitment to innovation and growth through its three main divisions: services, ventures, and medical. The report outlines the company’s strategic initiatives and financial performance, emphasizing its efforts to enhance stakeholder value and strengthen its position in the technology industry.

Hydrix Limited Resumes Trading on ASX

Hydrix Limited, a company listed on the Australian Securities Exchange, has announced that the suspension of its trading will be lifted. This follows the submission of its audited financial statements for the fiscal year ending June 30, 2025, indicating a return to compliance and resumption of normal trading activities.

Hydrix Limited Releases FY25 Audited Financial Statements with Revised Investment Valuation

Hydrix Limited has lodged its audited financial statements for the fiscal year ending June 30, 2025, after a delay due to an independent valuation report required by its auditor. The report led to a downward revision of the fair value of its investment in Wavewise Analytics Pty Ltd by $0.385 million, reflecting a new value of $0.375 million, compared to an initial investment of $0.50 million. This adjustment may impact stakeholders’ perception of Hydrix’s investment strategy and financial health.

Hydrix Limited Releases 2025 Financial Statements

Hydrix Limited, a public company based in Australia, has released its financial statements for the year ended 30 June 2025. The company operates as a consolidated entity, and its financial statements are presented in Australian dollars. The financial statements were authorized for issue by the directors on 10 October 2025, highlighting the company’s ongoing commitment to transparency and regulatory compliance.

Hydrix Limited Announces 2025 AGM and Director Nomination Deadline

Hydrix Limited has announced that its 2025 Annual General Meeting will take place on November 27, 2025, at 3:00 pm Melbourne time. The company also stated that the deadline for director nominations for this meeting is October 9, 2025. This announcement is part of the company’s ongoing efforts to engage with shareholders and ensure effective governance.

Hydrix Limited Faces Trading Suspension Due to Financial Statement Delay

Hydrix Limited announced a delay in the lodgement of its FY25 financial statements due to the need for an independent valuation report on its shares in Wavewise Analytics Pty Ltd. This delay will result in an automatic suspension of the company’s shares from trading on the ASX starting from October 1, 2025, until the statements are lodged, expected during the week commencing October 6, 2025.

Hydrix Limited Addresses ASX Query on Trading Activity

Hydrix Limited has responded to an ASX query regarding a recent increase in the price and trading volume of its securities, stating that it is not aware of any undisclosed information that could explain this activity. The company emphasizes its commitment to continuous disclosure obligations and confirms compliance with ASX Listing Rules.

Hydrix Limited Reports Improved Financial Performance Amid Revenue Decline

Hydrix Limited reported a decrease in revenue by 4.9% for the year ending 30 June 2025 compared to the previous year, while significantly reducing its losses by 69.5%. The company has improved its net cash used in operating activities, indicating a positive shift in financial management. Despite these improvements, no dividends are proposed, and the financial statements are still under audit, with an anticipated emphasis on the company’s going concern status.